Free Trial
NASDAQ:SEEL

Seelos Therapeutics (SEEL) Stock Price, News & Analysis

Seelos Therapeutics logo
$0.30 -0.19 (-38.77%)
(As of 11/22/2024 ET)

About Seelos Therapeutics Stock (NASDAQ:SEEL)

Key Stats

Today's Range
$0.27
$0.51
50-Day Range
$0.35
$5.41
52-Week Range
$0.37
$698.88
Volume
10,338 shs
Average Volume
22,881 shs
Market Capitalization
$111,637.20
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

Receive SEEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SEEL Stock News Headlines

50-year Wall Street legend: “Sell this tech stock NOW”
Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.
Seelos gets Nasdaq delisting notice
See More Headlines

SEEL Stock Analysis - Frequently Asked Questions

Seelos Therapeutics' stock was trading at $177.92 at the beginning of 2024. Since then, SEEL shares have decreased by 99.8% and is now trading at $0.3001.
View the best growth stocks for 2024 here
.

Shares of Seelos Therapeutics reverse split on the morning of Friday, September 27th 2024. The 1-16 reverse split was announced on Wednesday, September 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Seelos Therapeutics' top institutional shareholders include Modera Wealth Management LLC (0.50%).
View institutional ownership trends
.

Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Seelos Therapeutics investors own include Block (SQ), Digital Turbine (APPS), Palantir Technologies (PLTR), Okta (OKTA), CrowdStrike (CRWD), SoFi Technologies (SOFI) and ChargePoint (CHPT).

Company Calendar

Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SEEL
Employees
20
Year Founded
2016

Profitability

Net Income
$-37,880,000.00
Pretax Margin
203.13%

Debt

Sales & Book Value

Annual Sales
$2.20 million
Book Value
($437.92) per share

Miscellaneous

Free Float
368,000
Market Cap
$111,637.20
Optionable
Optionable
Beta
1.94

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:SEEL) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners